INM InMed Pharmaceuticals Inc. Stock Quote

INM [NASD]

Index	-	P/E	-	EPS (ttm)	-1.41	Insider Own	0.78%	Shs Outstand	8.05M	Perf Week	-3.51%
Market Cap	23.40M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	0.00%	Shs Float	8.01M	Perf Month	0.73%
Income	-8.60M	PEG	-	EPS next Q	-0.34	Inst Own	11.90%	Short Float	0.18%	Perf Quarter	-30.90%
Sales	-	P/S	-	EPS this Y	11.00%	Inst Trans	83.23%	Short Ratio	0.16	Perf Half Y	-7.56%
Book/sh	1.38	P/B	1.99	EPS next Y	-	ROA	-97.20%	Target Price	-	Perf Year	-60.64%
Cash/sh	1.12	P/C	2.46	EPS next 5Y	-	ROE	-132.90%	52W Range	2.55 - 8.94	Perf YTD	-16.41%
Dividend	-	P/FCF	-	EPS past 5Y	5.90%	ROI	-	52W High	-69.24%	Beta	1.43
Dividend %	-	Quick Ratio	6.40	Sales past 5Y	-	Gross Margin	-	52W Low	7.84%	ATR	0.23
Employees	13	Current Ratio	6.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.11	Volatility	9.46% 7.44%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	-6.00%	Profit Margin	-	Rel Volume	0.43	Prev Close	2.75
Shortable	Yes	LT Debt/Eq	0.02	Earnings	May 13	Payout	-	Avg Volume	85.57K	Price	2.75
Recom	-	SMA20	-4.98%	SMA50	-10.58%	SMA200	-25.09%	Volume	37,184	Change	0.00%

Jun-21-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021 GlobeNewswire
Jun-17-21 07:30AM	InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn in Advance of Commercial Scale Production GlobeNewswire
Jun-15-21 06:41AM	Is InMed Pharmaceuticals Inc. (INM) A Good Stock To Buy Now? Insider Monkey
Jun-09-21 11:30AM	InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference GlobeNewswire
May-13-21 09:15AM	InMed Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE -16.86%
07:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results GlobeNewswire
May-06-21 07:30AM	InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results GlobeNewswire
May-04-21 07:30AM	InMed to Present at Canaccord Genuitys 5th Annual Global Cannabis Conference on May 11th, 2021 GlobeNewswire
Apr-28-21 07:30AM	InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa GlobeNewswire +11.54%
Apr-27-21 07:30AM	InMed Pharmaceuticals Announces Voluntary Delisting from TSX GlobeNewswire -5.06%
Apr-26-21 07:30AM	InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn GlobeNewswire +24.04%
Mar-17-21 02:49PM	Ontario Lottery and Gaming Corporation - MidDay lottery winning numbers - March 17, 2021 CNW Group
Mar-03-21 06:00PM	InMed to Present at Virtual Conferences in March 2021 GlobeNewswire
Feb-26-21 08:00AM	IIROC Trading Halt - TTO.H CNW Group
Feb-16-21 07:30AM	InMed Announces Closing of US$4.5 Million Private Placement CNW Group
Feb-11-21 09:30AM	InMed Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE +6.15%
07:30AM	InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results PR Newswire
07:30AM	InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results CNW Group
Feb-08-21 07:04AM	Transnetyx Announces Acquisition of BrainBits® CNW Group
Feb-05-21 09:00PM	InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results PR Newswire -9.39%
12:15PM	InMed Pharmaceuticals Stock Drops After It Presses Capital Raise Button Benzinga
09:53AM	IIROC Trade Resumption - IN CNW Group
09:37AM	IIROC Trading Halt - IN CNW Group
09:34AM	InMed Announces US$4.5 Million Private Placement PR Newswire
09:34AM	InMed Announces US$4.5 Million Private Placement CNW Group
Feb-02-21 07:00AM	Orford Completes the Inaugural Exploration Program on its Joutel Properties. Next program to Begin Mid-February CNW Group
Feb-01-21 05:00AM	February is Heart Month, and after nearly 70 years, Heart & Stroke's signature fundraiser, the door-to-door Canvass goes 100% online CNW Group
Jan-26-21 08:00AM	Mackenzie Investments ETF Report: 2020 Was a Record-Breaking Year for Canadian ETF Industry CNW Group
Jan-19-21 02:00PM	InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe PR Newswire
Jan-18-21 07:00AM	Is InMed Pharmaceuticals (TSE:IN) In A Good Position To Invest In Growth? Simply Wall St.
Jan-08-21 07:30AM	InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects PR Newswire +6.33%
07:30AM	InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects CNW Group
Jan-05-21 04:52PM	InMed to Participate at Virtual Conferences in January 2021 PR Newswire
Dec-11-20 07:00AM	/R E M I N D E R -- Media Advisory - Prime Minister's itinerary for Friday, December 11, 2020/ CNW Group
Nov-25-20 07:30AM	InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects PR Newswire
Nov-24-20 08:00PM	InMed Announces Election of Directors PR Newswire
Nov-18-20 07:30AM	InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics PR Newswire +7.29%
07:30AM	InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics CNW Group
Nov-17-20 06:00AM	Lonely Planet's Best in Travel Picks for 2021 Reflect a New World for Travel CNW Group
Nov-16-20 11:42AM	InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering PR Newswire
Nov-13-20 07:30AM	InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results PR Newswire
Nov-12-20 09:10AM	InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM" PR Newswire -33.40%
09:10AM	InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM" CNW Group

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience